Acute Myocardial Infarction Market Projected to Offer Substantial Growth Opportunities, Reaching $1.95 Billion by 2029
Grab 20% Off With Code ONLINE20 On Global market Reports – Evaluate Global Trends, Market Risks, and Competitive Intelligence
What Is the Comparative Market Size of the Acute Myocardial Infarction Market Between 2025 and 2029?
The acute myocardial infarction market size has grown strongly in recent years. It will grow from $1.47 billion in 2024 to $1.56 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to a rise in smoking-related heart diseases, increasing prevalence of hypertension, improved emergency medical services, growing awareness of heart disease risk factors, and early use of aspirin in cardiovascular care.
The acute myocardial infarction market size is expected to see strong growth in the next few years. It will grow to " $1.95 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to rising demand for minimally invasive cardiac procedures, increasing investment in regenerative medicine for heart repair, rising prevalence of obesity and diabetes, and growing focus on personalized medicine for heart disease. Major trends in the forecast period include artificial intelligence (AI)-driven early detection systems, wearable ECG monitoring devices, nanotechnology-based drug delivery, three-dimensional (3D) bioprinting of cardiac tissues, and advanced robotic-assisted cardiac surgeries.
Get your free report sample today:
What Are the Underlying Growth Drivers for the Acute Myocardial Infarction Market?
The rising hypertension cases are expected to propel the growth of the acute myocardial infarction market going forward. Hypertension is a medical condition characterized by persistently high blood pressure, which increases the risk of heart disease, stroke, and other health complications. The hypertension cases are increasing due to the increasing prevalence of inactive lifestyles, caused by desk jobs, prolonged screen time, and minimal exercise. Hypertension contributes to acute myocardial infarction by damaging arteries, promoting plaque buildup, and increasing the risk of blood clots that can block coronary arteries. For instance, in October 2024, according to a report published by the Australian Bureau of Statistics, an Australia-based government agency, the prevalence of hypertension reached 11.6% (3.0 million people) in 2022. Therefore, the rising hypertension cases are driving the growth of the acute myocardial infarction market.
What Are the Major Segments Defining the Structure of the Acute Myocardial Infarction Market?
The acute myocardial infarctionmarket covered in this report is segmented –
1) By Type: ST-Elevation Myocardial Infarction (STEMI); Non-ST-Elevation Myocardial Infarction (NSTEMI)
2) By Treatment Type: Thrombolytic Therapy; Percutaneous Coronary Intervention (PCI); Coronary Artery Bypass Grafting (CABG); Medications
3) By Diagnosis Method: Electrocardiogram; Cardiac Biomarkers; Echocardiography; Coronary Angiography; Magnetic Resonance Imaging (MRI); Computed Tomography (CT) Scan
4) By Route Of Administration: Oral Route; Intravenous (IV) Route; Subcutaneous Route; Transdermal Route; Sublingual Route
5) By End User: Hospitals And Clinics; Ambulatory Surgical Centers; Specialty Cardiac Centers; Research Institutes
Subsegments:
1) ST-Elevation Myocardial Infarction (STEMI): Anterior ST-Elevation Myocardial Infarction (STEMI); Inferior ST-Elevation Myocardial Infarction (STEMI); Posterior ST-Elevation Myocardial Infarction (STEMI); Lateral ST-Elevation Myocardial Infarction (STEMI); Right Ventricular ST-Elevation Myocardial Infarction (STEMI); Extensive (Large) ST-Elevation Myocardial Infarction (STEMI)
2) Non-ST-Elevation Myocardial Infarction (NSTEMI): Subendocardial Non-ST-Elevation Myocardial Infarction (NSTEMI); Partial Thickness Non-ST-Elevation Myocardial Infarction (NSTEMI); Multi-Vessel Non-ST-Elevation Myocardial Infarction (NSTEMI); Silent Non-ST-Elevation Myocardial Infarction (NSTEMI); Recurrent Non-ST-Elevation Myocardial Infarction (NSTEMI)
Which Major Trends Are Expected to Define the Acute Myocardial Infarction Market Through 2029?
Major companies operating in the acute myocardial infarction market are focusing on obtaining regulatory approvals to expand their product portfolio, enhance treatment efficacy, and strengthen their market position. Regulatory approvals refer to official authorizations from health agencies such as the FDA and EMA, ensuring that drugs and medical devices meet safety, efficacy, and quality standards before market entry. For instance, in March 2025, Sungen Biomedical, a China-based biopharmaceutical company, received FDA Fast Track Designation for its monoclonal antibody drug, SGC001, the world's first developed for the emergency treatment of acute myocardial infarction (AMI). This designation recognizes SGC001’s potential to reduce cardiomyocyte apoptosis and improve blood flow in ischemic areas. With promising preclinical results indicating benefits in recovery and reduced mortality, Fast Track status enables expedited FDA communication, accelerating the approval process and ensuring quicker patient access to this innovative AMI therapy.
Which Firms Represent the Competitive Benchmark Within the Acute Myocardial Infarction Market?
Major companies operating in the acute myocardial infarction market are Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Siemens Healthineers, Fujifilm Holdings Corporation, Koninklijke Philips N.V., Boston Scientific Corporation, Daiichi Sankyo Company Limited, Terumo Corporation, MicroPort Scientific Corporation, Ionis Pharmaceuticals Inc., CellProthera, Athersys Inc., BioCardia Inc., Serca Pharmaceuticals.
Get the detailed acute myocardial infarction market report today
Which Regions Are Driving the Highest Demand in the Acute Myocardial Infarction Market?
North America was the largest region in the acute myocardial infarction market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute myocardial infarction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment